136 related articles for article (PubMed ID: 38053201)
1. Repressing HIF-1α-induced HDAC9 contributes to the synergistic effect of venetoclax and MENIN inhibitor in KMT2Ar AML.
Ling Q; Zhou Y; Qian Y; Qian J; Zhang Y; Wang J; Zhu Y; Zhou Y; Wei J; Yang C; Sun J; Yu W; Jin J; Zhang X
Biomark Res; 2023 Dec; 11(1):105. PubMed ID: 38053201
[TBL] [Abstract][Full Text] [Related]
2. Effective tumor cell abrogation via Venetoclax-mediated BCL-2 inhibition in KMT2A-rearranged acute B-lymphoblastic leukemia.
Richter A; Lange S; Holz C; Brock L; Freitag T; Sekora A; Knuebel G; Krohn S; Schwarz R; Hinz B; Murua Escobar H; Junghanss C
Cell Death Discov; 2022 Jul; 8(1):302. PubMed ID: 35778418
[TBL] [Abstract][Full Text] [Related]
3. Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation.
Nguyen D; Kantarjian HM; Short NJ; Qiao W; Ning J; Cuglievan B; Daver NG; DiNardo CD; Jabbour EJ; Kadia TM; Borthakur G; Garcia-Manero G; Konopleva MY; Andreeff M; Ravandi-Kashani F; Sasaki K; Issa GC
Cancer; 2023 Jun; 129(12):1856-1865. PubMed ID: 36892949
[TBL] [Abstract][Full Text] [Related]
4. Selinexor Synergistically Promotes the Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia by Inhibiting Glycolytic Function and Downregulating the Expression of DNA Replication Genes.
Jiang J; Wang Y; Liu D; Wang X; Zhu Y; Tong J; Chen E; Xue L; Zhao N; Liang T; Zheng C
Immunotargets Ther; 2023; 12():135-147. PubMed ID: 38026089
[TBL] [Abstract][Full Text] [Related]
5. Venetoclax and pegcrisantaspase for complex karyotype acute myeloid leukemia.
Emadi A; Kapadia B; Bollino D; Bhandary B; Baer MR; Niyongere S; Strovel ET; Kaizer H; Chang E; Choi EY; Ma X; Tighe KM; Carter-Cooper B; Moses BS; Civin CI; Mahurkar A; Shetty AC; Gartenhaus RB; Kamangar F; Lapidus RG
Leukemia; 2021 Jul; 35(7):1907-1924. PubMed ID: 33199836
[TBL] [Abstract][Full Text] [Related]
6. Combination of a New Oral Demethylating Agent, OR2100, and Venetoclax for Treatment of Acute Myeloid Leukemia.
Kamachi K; Ureshino H; Watanabe T; Yoshida-Sakai N; Fukuda-Kurahashi Y; Kawasoe K; Hoshiko T; Yamamoto Y; Kurahashi Y; Kimura S
Cancer Res Commun; 2023 Feb; 3(2):297-308. PubMed ID: 36860654
[TBL] [Abstract][Full Text] [Related]
7. Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine.
Buettner R; Nguyen LXT; Morales C; Chen MH; Wu X; Chen LS; Hoang DH; Hernandez Vargas S; Pullarkat V; Gandhi V; Marcucci G; Rosen ST
J Hematol Oncol; 2021 Apr; 14(1):70. PubMed ID: 33902674
[TBL] [Abstract][Full Text] [Related]
8. Not BCL2 mutation but dominant mutation conversation contributed to acquired venetoclax resistance in acute myeloid leukemia.
Zhang X; Qian J; Wang H; Wang Y; Zhang Y; Qian P; Lou Y; Jin J; Zhu H
Biomark Res; 2021 May; 9(1):30. PubMed ID: 33933163
[TBL] [Abstract][Full Text] [Related]
9. Targeting EZH2 Promotes Chemosensitivity of BCL-2 Inhibitor through Suppressing PI3K and c-KIT Signaling in Acute Myeloid Leukemia.
Yang C; Gu Y; Ge Z; Song C
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232694
[TBL] [Abstract][Full Text] [Related]
10. Acquired resistance to venetoclax plus azacitidine in acute myeloid leukemia: In vitro models and mechanisms.
Carter JL; Su Y; Qiao X; Zhao J; Wang G; Howard M; Edwards H; Bao X; Li J; Hüttemann M; Yang J; Taub JW; Ge Y
Biochem Pharmacol; 2023 Oct; 216():115759. PubMed ID: 37604291
[TBL] [Abstract][Full Text] [Related]
11. Panobinostat sensitizes AraC-resistant AML cells to the combination of azacitidine and venetoclax.
Zhao J; Wu S; Wang D; Edwards H; Thibodeau J; Kim S; Stemmer P; Wang G; Jin J; Savasan S; Taub JW; Ge Y
Biochem Pharmacol; 2024 Feb; ():116065. PubMed ID: 38373594
[TBL] [Abstract][Full Text] [Related]
12. Triple combination targeting methyltransferase, BCL-2, and PD-1 facilitates antileukemia responses in acute myeloid leukemia.
Zeng Z; Maiti A; Herbrich S; Cai T; Cavazos A; Manzella T; Ma H; Hayes K; Matthews J; DiNardo CD; Daver NG; Konopleva MY
Cancer; 2023 Feb; 129(4):531-540. PubMed ID: 36477735
[TBL] [Abstract][Full Text] [Related]
13. Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements.
Issa GC; Zarka J; Sasaki K; Qiao W; Pak D; Ning J; Short NJ; Haddad F; Tang Z; Patel KP; Cuglievan B; Daver N; DiNardo CD; Jabbour E; Kadia T; Borthakur G; Garcia-Manero G; Konopleva M; Andreeff M; Kantarjian HM; Ravandi F
Blood Cancer J; 2021 Sep; 11(9):162. PubMed ID: 34588432
[TBL] [Abstract][Full Text] [Related]
14. Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia.
Winters AC; Maloney KW; Treece AL; Gore L; Franklin AK
Pediatr Blood Cancer; 2020 Oct; 67(10):e28398. PubMed ID: 32735397
[TBL] [Abstract][Full Text] [Related]
15. Arsenic Trioxide and Venetoclax Synergize against AML Progenitors by ROS Induction and Inhibition of Nrf2 Activation.
Hoang DH; Buettner R; Valerio M; Ghoda L; Zhang B; Kuo YH; Rosen ST; Burnett J; Marcucci G; Pullarkat V; Nguyen LXT
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743010
[TBL] [Abstract][Full Text] [Related]
16. Menin Inhibitors in Acute Myeloid Leukemia-What Does the Future Hold?
Swaminathan M; Bourgeois W; Armstrong SA; Wang ES
Cancer J; 2022 Jan-Feb 01; 28(1):62-66. PubMed ID: 35072375
[TBL] [Abstract][Full Text] [Related]
17. Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia.
Fleischmann M; Scholl S; Frietsch JJ; Hilgendorf I; Schrenk K; Hammersen J; Prims F; Thiede C; Hochhaus A; Schnetzke U
J Cancer Res Clin Oncol; 2022 Nov; 148(11):3191-3202. PubMed ID: 35099591
[TBL] [Abstract][Full Text] [Related]
18. Novel Compounds Synergize With Venetoclax to Target KMT2A-Rearranged Pediatric Acute Myeloid Leukemia.
Tregnago C; Benetton M; Da Ros A; Borella G; Longo G; Polato K; Francescato S; Biffi A; Pigazzi M
Front Pharmacol; 2021; 12():820191. PubMed ID: 35153769
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy of Venetoclax Plus Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia Patients with
Weng GY; You WW; Liu HX; Cai Y; DU X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1333-1339. PubMed ID: 37846681
[TBL] [Abstract][Full Text] [Related]
20. Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis.
Hurrish KH; Su Y; Patel S; Ramage CL; Carter JL; Edwards H; Buck SA; Wiley SE; Hüttemann M; Polin L; Kushner J; Dzinic SH; White K; Bao X; Li J; Yang J; Boerner J; Hou Z; Al-Atrash G; Konoplev SN; Busquets J; Tiziani S; Matherly LH; Taub JW; Konopleva M; Ge Y; Baran N
Res Sq; 2023 Apr; ():. PubMed ID: 37162954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
